Impact of medication adherence on hospitalization risk and healthcare cost

Department of Medical Affairs, Medco Health Solutions, Inc., Franklin Lakes, New Jersey 07417, USA.
Medical Care (Impact Factor: 2.94). 07/2005; 43(6):521-30. DOI: 10.1097/
Source: PubMed

ABSTRACT The objective of this study was to evaluate the impact of medication adherence on healthcare utilization and cost for 4 chronic conditions that are major drivers of drug spending: diabetes, hypertension, hypercholesterolemia, and congestive heart failure.
The authors conducted a retrospective cohort observation of patients who were continuously enrolled in medical and prescription benefit plans from June 1997 through May 1999. Patients were identified for disease-specific analysis based on claims for outpatient, emergency room, or inpatient services during the first 12 months of the study. Using an integrated analysis of administrative claims data, medical and drug utilization were measured during the 12-month period after patient identification. Medication adherence was defined by days' supply of maintenance medications for each condition.
The study consisted of a population-based sample of 137,277 patients under age 65.
Disease-related and all-cause medical costs, drug costs, and hospitalization risk were measured. Using regression analysis, these measures were modeled at varying levels of medication adherence.
For diabetes and hypercholesterolemia, a high level of medication adherence was associated with lower disease-related medical costs. For these conditions, higher medication costs were more than offset by medical cost reductions, producing a net reduction in overall healthcare costs. For diabetes, hypercholesterolemia, and hypertension, cost offsets were observed for all-cause medical costs at high levels of medication adherence. For all 4 conditions, hospitalization rates were significantly lower for patients with high medication adherence.
For some chronic conditions, increased drug utilization can provide a net economic return when it is driven by improved adherence with guidelines-based therapy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Patient education on pharmacological therapy may increase medication adherence and decrease hospitalizations. Our aim is to evaluate the effectiveness of pharmaceutical care at emergency department discharge in patients with hypertension and/or diabetes. This is a randomized controlled trial. Participants will be recruited from a public emergency department at Restinga district in Porto Alegre, southern Brazil. A total of 380 patients will be randomly assigned into 2 groups at the moment of emergency department discharge after receiving medical orientations: an intervention group, consisting of a structured individual counseling session by a pharmacist in addition to written orientations, or a control group, consisting only of written information about the disease. Outcomes will be assessed in an ambulatory visit 2 months after the randomization. The primary outcome is the proportion of patients with high medication adherence assessed using the Morisky-Green Test and the Brief Medication Questionnaire. The secondary outcomes are reduction of blood pressure, glycated hemoglobin, fasting plasma glucose, quality of life and number of visits to the emergency department. Pharmaceutical care interventions have shown to be feasible and effective in increasing medication adherence in both hospital outpatient and community pharmacy settings. However, there have been no previous assessments of the effectiveness of pharmacy care interventions initiated in patients discharged from emergency departments. Our hypothesis is that pharmaceutical counseling is also effective in this population. registration number: NCT01978925 (11 November 2013) and Brazilian Registry of Clinical Trials U1111-1149-8922 (5 November 2013).
    Trials 12/2015; 16(1):579. DOI:10.1186/s13063-015-0579-3 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To synthesize current evidence on medication adherence rates and associated risk factors in patients after an acute coronary syndrome (ACS). A systematic review was conducted. Five electronic databases and article bibliographies were searched for publications from 1990 to 2013 which assessed adherence to secondary prevention pharmacotherapy in adults after hospital discharge for an ACS. Identified studies were screened using pre-defined criteria for eligibility. A standardized form was used for data abstraction. Methodological quality was assessed using modified criteria for quantitative studies. Seventeen studies met our inclusion criteria. Post-discharge medication adherence rates at 1-year ranged between 54% and 86%. There were no consistent predictors of non-adherence across all cardiac medication classes examined. Adherence to secondary prevention pharmacotherapy was suboptimal in patients after hospital discharge for an ACS. Risk factors associated with non-adherence were examined in a limited number of studies, and the associations varied between these investigations. Copyright © 2015 Elsevier Inc. All rights reserved.
    Heart and Lung The Journal of Acute and Critical Care 03/2015; DOI:10.1016/j.hrtlng.2015.02.004 · 1.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: To evaluate the quality of existing value-based insurance design (V-BID) program evaluations on medication adherence, and to identify areas of expansion for future V-BID policy research. Study Design: Literature review. Methods: A structured search of the peer-reviewed literature was performed using healthcare and economic databases for studies evaluating the impact of V-BID programs on medication adherence. Characteristics of V-BID programs that may result in biased estimates for V-BID effectiveness were assessed and evaluated. Results: A total of 20 studies assessing the effects of 17 V-BID programs were identified. Medication adherence generally improved after V-BID implementation (mean effect size 3.4% after 1 year). The V-BID evaluation literature suffers from several methodological issues, such as a lack of reporting on baseline and final adherence rates, or absolute adherence changes. Factors that may influence observed effect sizes include program characteristics, baseline adherence rates, disease category, and disease management programs. Effect sizes were much higher in studies where the primary author reported employment by the study firm or sponsor. Conclusions: Many of the studies evaluating V-BID programs suffered from a lack of clarity when describing the methods used, or a lack of transparency when reporting results, and much of the evidence comes from studies where potential conflicts of interest exist. Authors should ensure that baseline and/or final adherence values are reported in addition to effect sizes, consistent terminology is used throughout a study, results are assessed for potential bias due to confounding factors, and due diligence has been performed to eliminate alternative explanations.
    American Journal of Managed Care 02/2015; 21(1):e78-e90.

Full-text (2 Sources)

Available from
Jun 4, 2014